STOCK TITAN
  1. Home
  2. News
  3. INCY

Incyte Genomics Inc - INCY STOCK NEWS

Welcome to our dedicated page for Incyte Genomics news (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte Genomics stock.

Incyte Genomics Inc. (Symbol: INCY) is a leading biopharmaceutical company dedicated to the discovery, development, and commercialization of proprietary therapeutics, with a primary focus on oncology. Headquartered in Wilmington, Delaware, Incyte employs over 625 professionals across its management, discovery, clinical development, and commercial teams.

The company’s flagship product, Jakafi, is a groundbreaking treatment for rare blood cancers and graft versus host disease, developed in partnership with Novartis. Incyte has also made significant strides with its other marketed drugs, including Olumiant for rheumatoid arthritis (licensed to Eli Lilly), Iclusig for chronic myeloid leukemia, Pemazyre for cholangiocarcinoma, Tabrecta for lung cancer, and Monjuvi for diffuse large B-cell lymphoma. Additionally, Incyte's first dermatology product, Opzelura, received approval in 2021 for atopic dermatitis and in 2022 for vitiligo.

Incyte’s pipeline includes a wide array of innovative oncology and dermatology programs, demonstrating their commitment to addressing serious unmet medical needs. The company's strategic collaborations with major pharmaceutical firms further support the clinical development and global commercialization of its compounds.

Incyte’s financial health and robust portfolio position it strongly to continue improving patient lives while building sustainable value for its shareholders. For the latest updates on Incyte’s projects and developments, visit their corporate website at www.incyte.com.

News

Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI

Rhea-AI Summary
Incyte launches The Unseen Journey program using AI to visually depict the impact of myeloproliferative neoplasms (MPNs) on patients. The program transforms patient experiences into unique images to raise awareness and empathy for those with MPNs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
AI
-
News

Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease

Rhea-AI Summary
Incyte's axatilimab receives Priority Review acceptance for chronic GVHD treatment after positive AGAVE-201 trial results, showing promising efficacy and safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
none
-
News

Incyte to Present at Upcoming Investor Conference

Rhea-AI Summary
Incyte (INCY) to present at Cowen 44th Annual Health Care Conference on March 4, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
conferences
News

Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities

Rhea-AI Summary
Incyte (INCY) reports strong FY'23 with total net product and royalty revenues of $3.7 billion, a 14% increase YoY. Key highlights include Jakafi net revenues of $2.6 billion (+8%) and Opzelura cream net revenues of $109 million in Q4'23. The company aims for over 10 new launches by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
earnings
-
News

Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)

Rhea-AI Summary
Incyte has entered into an asset purchase agreement with MorphoSys AG, gaining exclusive global rights to tafasitamab, a humanized Fc-modified CD19-targeting immunotherapy marketed in the U.S. as Monjuvi® and outside of the U.S. as Minjuvi®. The new agreement allows Incyte to realize significant operating efficiencies and cost synergies. Incyte will now recognize revenue and cost for all U.S. commercialization and clinical development, and MorphoSys will no longer be eligible to receive future milestone, profit split, and royalty payments. Tafasitamab is approved in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and is currently in Phase 3 trials for multiple indications, including first-line DLBCL, relapsed or refractory follicular lymphoma (FL), and relapsed or refractory marginal zone lymphoma (MZL).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
none
-
News

Incyte to Report Fourth Quarter and Year-End 2023 Financial Results

Rhea-AI Summary
Incyte (Nasdaq:INCY) has scheduled its Q4 & YE 2023 financial results conference call and webcast for February 13, 2024. The press release will be at 7:00 a.m. ET, followed by the conference call at 8:00 a.m. ET. The company will provide a domestic and international dial-in number, along with a conference ID number for participation. A replay of the conference call will be available for thirty days, and the webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
conferences earnings
News

Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Incyte (INCY) highlights growth opportunities and provides key updates across its investigational pipeline and commercial portfolio at the 42nd Annual J.P. Morgan Healthcare Conference. The company announces new positive topline results from Phase 2 trial evaluating ruxolitinib cream (Opzelura®) in adults with hidradenitis suppurativa (HS) and preliminary results from Phase 1 study of INCB123667 (CDK2i). The presentation underscores potential high-impact launches across Oncology and Inflammation & Autoimmunity to drive sustainable long-term growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
none
-
News

Incyte to Present at Upcoming Investor Conferences

Rhea-AI Summary
Incyte (Nasdaq:INCY) will present at the Goldman Sachs Annual Healthcare CEOs Unscripted Conference on January 4, 2024, and at the 42nd Annual J. P. Morgan Healthcare Conference on January 8, 2024. The presentations will be webcast live and can be accessed at Investor.Incyte.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.45%
Tags
conferences
-
News

Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Rhea-AI Summary
Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) announced the successful results from the Phase 2 AGAVE-201 trial of axatilimab for chronic GVHD. The trial met its primary endpoint, with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first six months of treatment. The data were featured in the Plenary Scientific Session at the 65th American Society of Hematology Annual Meeting 2023. Incyte and Syndax expect to file a Biologics License Application (BLA) for axatilimab by year-end 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.28%
Tags
none
News

Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting

Rhea-AI Summary
Incyte (Nasdaq:INCY) will present more than 40 abstracts at the ASH 2023 conference, featuring data from its hematology and oncology products. The Plenary Scientific Session will showcase the results of the AGAVE-201 trial evaluating axatilimab in patients with chronic GVHD. Incyte will also host an analyst and investor event to discuss the key data presentations at ASH.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
none

FAQ

What is the current stock price of Incyte Genomics (INCY)?

The current stock price of Incyte Genomics (INCY) is $71.72 as of November 22, 2024.

What is the market cap of Incyte Genomics (INCY)?

The market cap of Incyte Genomics (INCY) is approximately 13.6B.

What is Incyte Genomics Inc. known for?

Incyte Genomics Inc. is known for its development and commercialization of proprietary therapeutics, primarily focused on oncology and dermatology.

Where is Incyte Genomics Inc. headquartered?

Incyte Genomics Inc. is headquartered in Wilmington, Delaware.

What is Jakafi?

Jakafi is Incyte's lead drug, used to treat rare blood cancers and graft versus host disease, in collaboration with Novartis.

Which drugs has Incyte marketed?

Incyte has marketed drugs including Olumiant for rheumatoid arthritis, Iclusig for chronic myeloid leukemia, Pemazyre for cholangiocarcinoma, Tabrecta for lung cancer, and Monjuvi for diffuse large B-cell lymphoma.

What is Opzelura used for?

Opzelura is Incyte’s first dermatology product, approved for atopic dermatitis in 2021 and for vitiligo in 2022.

Does Incyte collaborate with other pharmaceutical companies?

Yes, Incyte has established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of its compounds.

How many employees work at Incyte?

Incyte employs over 625 professionals.

What is Incyte's vision?

Incyte's vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs.

How can I get more information about Incyte?

More information about Incyte can be found on their corporate website at www.incyte.com.

What areas does Incyte's pipeline cover?

Incyte's pipeline includes a broad array of oncology and dermatology programs.

Stock INCY logo
Incyte Genomics Inc

Nasdaq:INCY

INCY Rankings

#715 Ranked by Market Cap
N/A Ranked by Dividends

INCY Stock Data

13.56B
188.30M
2.04%
97.86%
3.85%
Biotechnology
Services-commercial Physical & Biological Research
Link
United States of America
WILMINGTON